EXPRESS METHOD FOR DETERMINATION OF ENALAPRIL AND ENALAPRILAT IN HUMAN SERUM BY HPLC-MS/MS
Abstract
The express method for simultaneous determination of enalapril and enalaprilat in human serum using HPLC-MS/MS is proposed. A simple sample preparation procedure, short analysis time, and a wide analytical range for both analytes (5.00 to 250.00 ng/mL) characterize this method. This technique is useful for carrying out routine research, such as therapeutic drug monitoring, bioequivalence studies and evaluation of the interchangeability of enalapril drug products.
About the Authors
T. A. Rodina
Scientific Center for Expertise of Medicinal products of the Ministry of Health; The Moscow Department of Health I.V. Davydovsky City Clinical Hospital
Russian Federation
Russian Federation
E. S. Melnikov
The Moscow Department of Health I.V. Davydovsky City Clinical Hospital; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
S. A. Belkov
Scientific Center for Expertise of Medicinal products of the Ministry of Health; The Moscow Department of Health I.V. Davydovsky City Clinical Hospital; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. V. Sokolov
Scientific Center for Expertise of Medicinal products of the Ministry of Health; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. B. Prokofiev
Scientific Center for Expertise of Medicinal products of the Ministry of Health; The Moscow Department of Health I.V. Davydovsky City Clinical Hospital; I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. S. Sivkov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. G. Mancia et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // Blood pressure. 2013. V. 22. №. 4. P. 193-278.
2. G. Mancia et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // Blood pressure. 2009. V. 18. №. 6. P. 308-347.
3. Prospective Studies Collaboration et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // The Lancet. 2002. V. 360. №. 9349. P. 1903-1913.
4. И.Е. Чазова, Л.Г. Ратова. Комбинированная терапия у пациентов с артериальной гипертонией // Системные гипертензии. 2010. Т. 2. С. 6-10.
5. Ю.Н. Беленков, Р.Г. Оганов. Кардиология: нац. рук. - М.: ГЭОТАР-Медиа, 2008. 1232 с.
6. Ю.Н. Беленков, В.Ю. Мареев, Ф.Т. Агеев. Ингибиторы ангиотензин-превращающего фермента в лечении сердечно-сосудистых заболеваний (Квинаприл и эндотелиальная дисфункция). - М.: Инсайт полиграфик, 2002. 86 с.
7. M. Regulski et al. Chemistry and pharmacology of angiotensin-converting enzyme inhibitors // Current pharmaceutical design. 2015. V. 21. № 13. P. 1764-1775.
8. Распоряжение Правительства Российской Федерации от 26.12.2015 № 2724-р.
9. R. Thomsen et al. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors // Drug Metabolism and Disposition. 2014. V. 42. № 1. P. 126-133.
10. S. Casey Laizure et al. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? // Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2013. V. 33. № 2. P. 210-222.
11. Y. Yang et al. Enzyme-mediated hydrolytic activation of prodrugs // Acta Pharmaceutica Sinica B. 2011. V. 1. № 3. P. 143-159.
12. V.K. Holenarsipur et al. Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models // Biopharmaceutics & drug disposition. 2015. V. 36. № 6. P. 385-397.
13. J.C. Sanford et al. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus // Pharmacogenetics and genomics. 2016. V. 26. № 5. P. 197-207.
14. X. Wang et al. CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors // The pharmacogenomics journal. 2015. V. 16. № 3. P. 220-230.
15. Руководство по экспертизе лекарственных средств. Т. I. / Под. ред. проф. А.Н. Миронова. - М.: Гриф и К, 2013. 328 с.
16. Т.А. Родина, Е.С. Мельников, А.В. Соколов, А.Б. Прокофьев, В.В. Архипов, А.А. Аксёнов, Д.Л. Поздняков. Экспресс-методика определения карбамазепина и карбамазепин-10,11-эпоксида методом ВЭЖХ-МС/МС // Химико-фармацевтический журнал. 2016. Т. 50. № 6. С. 52-56.
17. Т.А. Родина, Е.С. Мельников, А.В. Соколов, С.А. Белков, Г.В. Раменская. Определение эналаприла и его активного метаболита эналаприлата в плазме крови методом ВЭЖХ-МС/МС при персонализации фармакотерапии больных артериальной гипертензией // Экспериментальная и клиническая фармакология. 2015. Т. 78. № 10. С. 15-20.
Review
For citations:
Rodina T.A., Melnikov E.S., Belkov S.A., Sokolov A.V., Prokofiev A.B., Sivkov A.S. EXPRESS METHOD FOR DETERMINATION OF ENALAPRIL AND ENALAPRILAT IN HUMAN SERUM BY HPLC-MS/MS. Drug development & registration. 2016;(4):184-189. (In Russ.)
Views:
741
Email this article 